Autoimmune thyroiditis CRP association


  • Melih Pamukcu Department of Rheumatology, Malatya Training and Research Hospital, Malatya, Turkey
  • Atilla Badem Department of Surgery, Faculty of Medicine, Yildirim Beyazit University, Ankara, Turkey
  • Omer Parlak Department of Surgery, Faculty of Medicine, Yildirim Beyazit University, Ankara, Turkey



Autoimmunity, C-reactive protein, Hypothyroidism, Overt, Subclinical


Background: C-reactive protein (CRP) is an acute phase reactant and its serum levels may be risen during many diseases. Hypothyroidism is a clinical disease state accompanied by mild inflammation that is known to be significantly associated with atherosclerosis. In this study, we aim to determine and compare serum CRP levels in overt and subclinical hypothyroidism subgroups and research their association with autoimmune markers.

Methods: Around 79 patients who are diagnosed with overt and subclinical hypothyroidism in our polyclinic were included in this study. Patients’ morning blood samples were collected after 8hours of fast and thyroid functions, CRP, sedimentation rate, anti TG and anti TPO antibody levels were studied. Thyroid ultrasonography was planned for each patient.

Results: We found significant differences regarding age, sT3, sT4, TSH, anti-TPO, anti-TG and CRP levels between overt and subclinical groups. There was no significant difference between the groups in thyroxin use, nodularity and sedimentation rate. No significant difference was found between CRP levels and autoimmunity markers anti-TPO and anti-TG among the groups as well. A significant cut-off value was determined for CRP in overt hypothyroidism by using Roc analysis and this value was also considered for being a possible cardiovascular risk marker.

Conclusions: In this study, we found out that CRP levels were high in both overt and subclinical subgroups, CRP levels were increased during progression of the disease from subclinical to overt and this increase may be related with higher inflammation and tendency to cardiovascular diseases. 


DeGroat LJ, Larsen RP. The thyroid and its disease. Churchill Livingstone Company, New York 6. Baski. 1996.

McCarty M. Historical perspective on C-reactive protein. Ann N Y Acad Sci. 1982;389:1-10.

Van Lente F. The Diagnostic Utility of C-reactive protein. Human Pathol. 1982;13:1061-3.

Hurlimann J, Thorbecke G, Hochwald G. The liver as the site of C-reactive protein formation. J Exp Med. 1966;123:365-78.

Macintyre S. C-reactive protein. Methods Enzymol. 1988;163:383-99.

Marley JJ, Kushner I. Serum C-reactive protein levels in disease. Ann N Y Acad Sci. 1982;389:406-18.

Venditti M, Brandimarte C, Trobiani P, Fenu S, Martino P, Serra P, et al. Serial study of C-reactive protein for the diagnosis of bacterial and fungal infections in neutropenic patients with hematologic malignancies. Haematologica. 1988;73(4):285-91.

Tuzcu A, Bahceci M, Gokalp D, Tuzun Y, Gunes K. Subclinical hypothyroidism may be associated with elevated high-sensitive c-reactive protein (low grade inflammation) and fasting hyperinsulinemia. Endocrine J. 2005;52(1):89-94.

Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Annals internal medicine. 2000 Feb 15;132(4):270-8.

Wells BJ, Hueston WJ. Are thyroid peroxidase antibodies associated with cardiovascular disease risk in patients with subclinical hypothyroidism. Clinical Endocrinology. 2005;62:580-4.

Christ-Crain M, Meier C, Guglielmetti M, Huber PR, Riesen W, Staub JJ, et al. Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis. 2003 Feb 1;166(2):379-86.

Nagasaki T, Inaba M, Shirakawa K, Hiura Y, Tahara H, Kumeda Y, et al. Increased levels of C-reactive protein in hypothyroid patients and its correlation with arterial stiffness in the common carotid artery. Biomedicine Pharmacotherapy. 2007 Feb 1;61(2-3):167-72.

Lee WY, Suh JY, Rhee EJ, Park JS, Sung KC, Kim SW. Plasma CRP, apolipoprotein A-1, apolipoprotein B and Lp (a) levels according to thyroid function status. Archives Med Res. 2004 Nov 1;35(6):540-5.

Jublanc C, Bruckert E, Giral P, Chapman MJ, Leenhardt L, Carreau V, et al. Relationship of circulating C-reactive protein levels to thyroid status and cardiovascular risk in hyperlipidemic euthyroid subjects: low free thyroxine is associated with elevated hsCRP. Atherosclerosis. 2004 Jan 1;172(1):7-11.

Hueston WJ, King DE, Geesey ME. Serum biomarkers for cardiovascular inflammation in subclinical hypothyroidism. Clinical Endocrinology. 2005;63:582-7.

Toruner F, Altinova AE, Karakoc A, Yetkin I, Ayvaz G, Cakir N, et al. Risk factors for cardiovascular disease in patients with subclinical hypothyroidism. Advances in therapy. 2008 May 1;25(5):430.

Napoli R, Guardasole V, Zarra E, D’Anna C, De Sena A, Lupoli GA, et al. Impaired endothelial‐and nonendothelial‐mediated vasodilation in patients with acute or chronic hypothyroidism. Clinical endocrinology. 2010 Jan;72(1):107-11.




How to Cite

Pamukcu, M., Badem, A., & Parlak, O. (2018). Autoimmune thyroiditis CRP association. International Journal of Research in Medical Sciences, 6(10), 3270–3275.



Original Research Articles